



Stock # 45-10777


Lipid Treatment Algorithm for Type 1 and Type 2 Diabetes Mellitus in Adults



Approved 08-23-01

FLP Goals:

LDL-C < 100 mg/dL
HDL-C ≥ 40 mg/dL
TG < 150 mg/dL



Legend

TLC = Therapeutic Lifestyle Changes (refer to TDC Nutrition and Exercise algorithms)

Statin = HMG Co-A Reductase Inhibitor **

ASD = Atherosclerotic Disease

TG = Triglycerides

Non-HDL-C = TC minus HDL-C

* Use with caution in patients with diabetes. Need to closely follow self-monitoring blood glucose (SMBG) as may worsen glycemic control. Recheck FLP and ALT 2–3 months after drug therapy initiation/titration. If patient develops myalgias, hold lipid-lowering drug and check CPK as soon as possible. See web site (<http://www.tdh.state.tx.us/diabetes/tdc.htm>) for latest version. ** See reverse side for more information.

Lipid Treatment Algorithm for Type 1 and Type 2 Diabetes Mellitus in Adults

HMG Co-A Reductase Inhibitors LDL-C Equivalency in Patients with Hypercholesterolemia					
Fluvastatin	Lovastatin	Pravastatin	Simvastatin	Atorvastatin	↓ LDL (%)
20mg	10mg	10mg	-----	-----	17-19
40mg	20mg	20mg	5-10mg	-----	23-29
80mg	40mg	40mg	20mg	10mg	31-38
-----	80mg	-----	40mg	20mg	41-46
-----	-----	-----	80mg	40mg	48-54
-----	-----	-----	-----	80mg	60

Am J Cardiol 1998; 81: 582-7. *The Medical Letter* May 2001; 43 (issue 1105). *NEJM* 1999; 341; 498-511.

Pharmaceutical manufacturer's package insert

Adapted from: National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) *JAMA* 2001;285(19):2466-97.

American Diabetes Association Clinical Practice Recommendations, Management of Dyslipidemia in Adults with Diabetes *Diabetes Care* 2001; 24 (supplement 1):1-8.

Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients with Diabetes and Peripheral Arterial Disease (The ADMIT Study: A Randomized Trial) *JAMA* 2000; 284 (10):1263-70.